Sinovac's vaccine trial data suggest potential in virus defence
[BEIJING] Sinovac Biotech said its coronavirus shot is safe and capable of eliciting an immune response from human trials, suggesting the shot's potential in defending against infection of the novel coronavirus.
The Beijing-based company's vaccine, called CoronaVac, hasn't caused severe side effects and more than 90 per cent of people administered with the shot on a 14-day interval have induced neutralising antibodies two weeks after inoculation, Sinovac said in a press release on Sunday. The preliminary findings come from phase one and two trials in China. A total of 743 healthy people ages 18 to 59 either received shots on two schedules or a placebo. More data will be uncovered from another group in the trial that received shots on a 28-day interval. Sinovac plans to publish its results in academic journals, according to a company spokesperson.
Using a killed version of the coronavirus, Sinovac's vaccine is among five Chinese experimental shots that have reached the crucial final stage of human testing before they can be approved for public use. The company announced a partnership this month with Instituto Butantan to conduct its phase three trial in Brazil, where the novel pathogen has caused the second-largest outbreak in a global pandemic that so far infected more than 7.7 million people and killed over 428,000.
Since lockdowns and social-distancing measures have helped to keep infection rates low in many countries, some of the world's leading vaccine efforts are seeking to conduct phase three trials in active outbreaks to evaluate the effectiveness of their shots.
Authorities in Brazil have approved the vaccine co-developed by the University of Oxford and AstraZeneca Plc to carry out late stage trials there, while Cambridge, Massachusetts-based Moderna is set to go into phase three trials in the US.
BLOOMBERG
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue